Cumberland Pharmaceuticals
CPIX
23 hedge funds and large institutions have $3.63M invested in Cumberland Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 3 closing their positions.
8,000% more call options, than puts
Call options by funds: $81K | Put options by funds: $1K
0.51% more ownership
Funds ownership: 14.74% → 15.25% (+0.51%)
7% less capital invested
Capital invested by funds: $3.89M → $3.63M (-$253K)
8% less funds holding
Funds holding: 25 → 23 (-2)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$3.36K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$237 |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$199 |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$174 |
| 5 |
JP Morgan Chase
New York
|
+$16 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
P
&Partners
Nashville,
Tennessee
|
-$19.7K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$16.6K |
| 3 |
Renaissance Technologies
New York
|
-$14.4K |
| 4 |
State Street
Boston,
Massachusetts
|
-$12.1K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$3.69K |
CPIX Hedge Fund Activity: Q1 2024 in Review
23 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q1 2024, worth a combined $3.63M — down 6.5% from $3.89M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CPIX and 1 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 5 added.
The largest buyer was UBS Group, adding an estimated $3.36K. The largest seller was &Partners, exiting entirely with an estimated $19.7K sold.
- 23 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q1 2024, down from 25 in Q4 2023.
- Funds reported $3.63M of Cumberland Pharmaceuticals stock for Q1 2024, down 6.5% quarter-over-quarter.
- 1 fund opened new Cumberland Pharmaceuticals positions in Q1 2024 and 3 closed out, a net change of -2 holders.
- The largest Cumberland Pharmaceuticals buyer in Q1 2024 was UBS Group, an estimated $3.36K added.
- The largest Cumberland Pharmaceuticals seller in Q1 2024 was &Partners, an estimated $19.7K sold.
Based on aggregated 13F filings for Q1 2024.